Work

VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.tps259

Authors: A. Oliver Sartor, Michael J. Morris, Richard Messman, Bernd J. Krause

Institutions: Tulane University, Memorial Sloan Kettering Cancer Center, Endocyte (United States), Universitätsmedizin Rostock

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947722113

Cites:

Cited by: 44

Related to: 10